FDA has announced it has expanded the approved use of Humira (adalimumab), manufactured by Abbott Laboratories, to include treatment of moderate-to-severe ulcerative colitis in adults, according to a ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

WASHINGTON, Aug 24 (Reuters) - Abbott Laboratories Inc may need to conduct additional trials of Humira to prove the blockbuster drug helps patients with ulcerative colitis, U.S. drug reviewers said on ...

Biologics in IBD: More Thoughtful Use Could Improve Outcomes The marketplace introduction of infliximab for the treatment of IBD did not reduce hospitalization or surgery rates in a large population ...

AbbVie's stock has risen to an all-time high, raising the question of whether it's still a good buy, especially as the market multiples look elevated from a historical perspective. Progress on its ...

Boehringer Ingelheim and GoodRx are launching a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available ...